Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.75% Market Closed
Market Cap: 3.6B USD

Axonics Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Axonics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Axonics Inc
NASDAQ:AXNX
Cash from Operating Activities
$14.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Cash from Operating Activities
$3.4B
CAGR 3-Years
9%
CAGR 5-Years
-1%
CAGR 10-Years
7%
Boston Scientific Corp
NYSE:BSX
Cash from Operating Activities
$4.6B
CAGR 3-Years
57%
CAGR 5-Years
25%
CAGR 10-Years
21%
Stryker Corp
NYSE:SYK
Cash from Operating Activities
$4.8B
CAGR 3-Years
23%
CAGR 5-Years
12%
CAGR 10-Years
18%
Abbott Laboratories
NYSE:ABT
Cash from Operating Activities
$9.1B
CAGR 3-Years
-4%
CAGR 5-Years
7%
CAGR 10-Years
10%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash from Operating Activities
$3B
CAGR 3-Years
22%
CAGR 5-Years
16%
CAGR 10-Years
16%
No Stocks Found

Axonics Inc
Glance View

Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.

AXNX Intrinsic Value
36.17 USD
Overvaluation 49%
Intrinsic Value
Price

See Also

What is Axonics Inc's Cash from Operating Activities?
Cash from Operating Activities
14.3m USD

Based on the financial report for Sep 30, 2024, Axonics Inc's Cash from Operating Activities amounts to 14.3m USD.

What is Axonics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
741%

Over the last year, the Cash from Operating Activities growth was 741%.

Back to Top